

June 1, 2018



Interpace Diagnostics Presents New Data on PancraGEN® at Digestive Disease Week

WASHINGTON, June 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the "Company" or "Interpace"), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that the Company will be presenting new data on the incremental value of PancraGEN® to patient outcomes when used as a companion molecular diagnostic to traditional imaging modalities. The results will be presented at the Digestive Disease Week® (DDW) meeting being held in Washington, D.C. June 2nd-5th, 2018. The work being presented is entitled "Risk of Malignancy in Pancreatic Cystic Lesions Triaged by Clinical and Molecular Features." Authors include Dr. James Farrell of the Yale Center for Pancreatic Disease (presenting author), Dr. Tamas Gonda of the Division of Digestive and Liver Disease, Columbia University Medical Center, and Dr. Mohammad Al-Haddad of Indiana University.

According to Syd Finkelstein, Chief Medical & Scientific Officer of Interpace, "the results from this collaboration with these highly regarded institutions clearly indicates that PancraGEN® provides incremental insights to physicians as it relates to understanding their individual patients' risk of progressing to pancreatic cancer." Dr. Finkelstein continued, "these data should give physicians a high degree of confidence in their treatment approach." In addition, Jack Stover, President & CEO of Interpace, stated, "we are especially pleased to present PancraGEN® for the first time as a companion product to traditional imaging, which we believe provides a new method to assist physicians in making accurate diagnoses and treatment decisions."

About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place June 2nd-5th at the Walter E. Washington Convention Center in Washington, D.C. and is expected to be attended by more than 14,000 professionals. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

About PancraGEN®

PancraGEN® is a molecular, pancreatic cancer risk classifier for cysts, solid lesions, and

biliary strictures that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is one of the leading causes of cancer deaths.

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being "soft launched" with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US and over time can progress to esophageal cancer. The Company's data base includes data from over 45,000 patients who have been tested using the Company's current products, including over 15,000 molecular tests for thyroid nodules. Interpace has been designated as one of the top 20 companies for providing bioinformatics solutions. Interpace's mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace's website at www.interpacediagnostics.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's history of losses, the Company's ability to adequately finance the business, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the "Risk Factors" detailed from time to time in the Company's SEC filings, including its Annual

Report on Form 10-K for the fiscal year ended December 31, 2017, filed on March 23, 2018, Quarterly Reports on Form 10-Q and other SEC filings.

Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace Diagnostics
Investor Relations:

Joe Green – Edison Group
(646) 653-7030
jgreen@edisongroup.com

Andrew Gibson – Edison Group
(646) 653-7719
agibson@edisongroup.com



Source: Interpace Diagnostics Group, Inc.